OVIT (OncoVista Innovative Therapies) Cyclically Adjusted Revenue per Share: $0.00 (As of Sep. 2015)


What is OncoVista Innovative Therapies Cyclically Adjusted Revenue per Share?

OncoVista Innovative Therapies OVIT Cyclically Adjusted Revenue per Share is $0.00 as of Sep. 2015.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

OncoVista Innovative Therapies's adjusted revenue per share for the three months ended in Sep. 2015 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Sep. 2015.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-01), OncoVista Innovative Therapies's current stock price is $0.0001. OncoVista Innovative Therapies's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2015 was $0.00. OncoVista Innovative Therapies's Cyclically Adjusted PS Ratio of today is .


OncoVista Innovative Therapies  (OTCPK:OVIT) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


OncoVista Innovative Therapies Cyclically Adjusted Revenue per Share Related Terms


OncoVista Innovative Therapies Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for OncoVista Innovative Therapies's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoVista Innovative Therapies Cyclically Adjusted Revenue per Share Chart

OncoVista Innovative Therapies Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OncoVista Innovative Therapies Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OVIT vs RSPI, HSTC, CAPS: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, OncoVista Innovative Therapies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoVista Innovative Therapies Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoVista Innovative Therapies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where OncoVista Innovative Therapies's Cyclically Adjusted PS Ratio falls into.



OncoVista Innovative Therapies Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, OncoVista Innovative Therapies's adjusted Revenue per Share data for the three months ended in Sep. 2015 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2015 (Change)*Current CPI (Sep. 2015)
=0/237.9450*237.9450
=0.000

Current CPI (Sep. 2015) = 237.9450.

OncoVista Innovative Therapies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200512 0.003 196.800 0.004
200603 0.002 199.800 0.002
200606 0.001 202.900 0.001
200609 0.002 202.900 0.002
200612 0.109 201.800 0.129
200703 0.030 205.352 0.035
200706 0.004 208.352 0.005
200709 0.015 208.490 0.017
200712 0.063 210.036 0.071
200803 0.004 213.528 0.004
200806 0.004 218.815 0.004
200809 0.005 218.783 0.005
200812 0.014 210.228 0.016
200903 0.010 212.709 0.011
200906 0.015 215.693 0.017
200909 0.013 215.969 0.014
200912 -0.037 215.949 -0.041
201003 0.000 217.631 0.000
201006 0.000 217.965 0.000
201009 0.000 218.439 0.000
201012 0.000 219.179 0.000
201103 0.000 223.467 0.000
201106 0.000 225.722 0.000
201109 0.000 226.889 0.000
201112 0.000 225.672 0.000
201203 0.000 229.392 0.000
201206 0.000 229.478 0.000
201209 0.000 231.407 0.000
201212 0.000 229.601 0.000
201303 0.000 232.773 0.000
201306 0.000 233.504 0.000
201309 0.000 234.149 0.000
201312 0.000 233.049 0.000
201403 0.000 236.293 0.000
201406 0.000 238.343 0.000
201409 0.000 238.031 0.000
201412 0.000 234.812 0.000
201503 0.000 236.119 0.000
201506 0.000 238.638 0.000
201509 0.000 237.945 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.00 mean?
OncoVista Innovative Therapies (OVIT) has a Cyclically Adjusted Revenue per Share of $0.00 as of Sep. 2015. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on OncoVista Innovative Therapies and its competitors.
Is OncoVista Innovative Therapies' Cyclically Adjusted Revenue per Share too high?
OncoVista Innovative Therapies' current Cyclically Adjusted Revenue per Share is $0.00.
How does OncoVista Innovative Therapies' Cyclically Adjusted Revenue per Share compare to RSPI and HSTC?
OncoVista Innovative Therapies' Cyclically Adjusted Revenue per Share of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on OncoVista Innovative Therapies and its competitors. OncoVista Innovative Therapies's current Cyclically Adjusted Revenue per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoVista Innovative Therapies stock overvalued right now?
OncoVista Innovative Therapies (OVIT) has a current Cyclically Adjusted Revenue per Share of $0.00. The current Cyclically Adjusted Revenue per Share is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For OncoVista Innovative Therapies (OVIT), the current Cyclically Adjusted Revenue per Share is $0.00 as of Sep. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OncoVista Innovative Therapies Business Description

Address 14785 Omicron Drive, Suite 104, San Antonio, TX, USA, 78245
OncoVista Innovative Therapies Inc is a biopharmaceutical company. It is engaged in developing anticancer therapies by utilizing tumor-associated biomarkers.